New Results From Bright Metal-Poor Stars In The Hamburg/Eso Survey

We present an abundance analysis of BE 1327-2326, currently the most iron-poor star known, based on a newly acquired VLT spectrum. The ID abundance pattern is corrected for 3D effects. The 3D iron abundance is [Fe/H] = -5.9, while the CNO elements of the star are extremely overabundant [CNO[Fe] similar to 3 to 4). The cosmologically important element Li is still not detected; the new upper limit is A (Li) < 0.6. A new analysis of the medium-resolution data of the sample of bright metal-poor stars from the Hamburg/ESO Survey (HES) was carried out. We are using this sample to obtain clues to the chemical nature of the early Universe by investigating the kinematic properties of the sample. Based on estimated [Fe/H] and [C/Fe], we are also able to use the sample to test a formation mechanism for low-mass metal-poor stars.Astronom

Carbon and Strontium Abundances of Metal-Poor Stars

We present carbon and strontium abundances for 100 metal-poor stars measured from R$\sim$7000 spectra obtained with the Echellette Spectrograph and Imager at the Keck Observatory. Using spectral synthesis of the G-band region, we have derived carbon abundances for stars ranging from [Fe/H]$=-1.3$ to [Fe/H]$=-3.8$. The formal errors are $\sim 0.2$ dex in [C/Fe]. The strontium abundance in these stars was measured using spectral synthesis of the resonance line at 4215 {\AA}. Using these two abundance measurments along with the barium abundances from our previous study of these stars, we show it is possible to identify neutron-capture-rich stars with our spectra. We find, as in other studies, a large scatter in [C/Fe] below [Fe/H]$= -2$. Of the stars with [Fe/H]$<-2$, 9$\pm$4% can be classified as carbon-rich metal-poor stars. The Sr and Ba abundances show that three of the carbon-rich stars are neutron-capture-rich, while two have normal Ba and Sr. This fraction of carbon enhanced stars is consistent with other studies that include this metallicity range.Comment: ApJ, Accepte

Carbon-Enhanced Metal-Poor Stars. III. Main-Sequence Turn-Off Stars from the SDSS/SEGUE Sample

The chemical compositions of seven Carbon-Enhanced Metal-Poor (CEMP) turn-off stars are determined from high-resolution spectroscopy. Five of them are selected from the SDSS/SEGUE sample of metal-poor stars. The effective temperatures of these objects are all higher than 6000 K, while their metallicities, parametrized by [Fe/H], are all below -2. Six of our program objects exhibit high abundance ratios of barium ([Ba/H]> +1), suggesting large contributions of the products of former AGB companions via mass transfer across binary systems. Combining our results with previous studies provides a total of 20 CEMP main-sequence turn-off stars for which the abundances of carbon and at least some neutron-capture elements are determined. Inspection of the [C/H] ratios for this sample of CEMP turn-off stars show that they are generally higher than those of CEMP giants; their dispersion in this ratio is also smaller. We take these results to indicate that the carbon-enhanced material provided from the companion AGB star is preserved at the surface of turn-off stars with no significant dilution. In contrast, a large dispersion in the observed [Ba/H] is found for the sample of CEMP turn-off stars, suggesting that the efficiency of the s-process in very metal-poor AGB stars may differ greatly from star to star. Four of the six stars from the SDSS/SEGUE sample exhibit kinematics that are associated with membership in the outer-halo population, a remarkably high fraction.Comment: 45 pages, 10 figures, 10 tables, Astrophysical Journal, in pres

Imaging Extended Emission-Line Regions of Obscured AGN with the Subaru Hyper Suprime-Cam Survey

Narrow-line regions excited by active galactic nuclei (AGN) are important for studying AGN photoionization and feedback. Their strong [O III] lines can be detected with broadband images, allowing morphological studies of these systems with large-area imaging surveys. We develop a new technique to reconstruct the [O III] images using the Subaru Hyper Suprime-Cam (HSC) Survey aided with spectra from the Sloan Digital Sky Survey (SDSS). The technique involves a careful subtraction of the galactic continuum to isolate emission from the [O III]$\lambda$5007 and [O III]$\lambda$4959 lines. Compared to traditional targeted observations, this technique is more efficient at covering larger samples with less dedicated observational resources. We apply this technique to an SDSS spectroscopically selected sample of 300 obscured AGN at redshifts 0.1 - 0.7, uncovering extended emission-line region candidates with sizes up to tens of kpc. With the largest sample of uniformly derived narrow-line region sizes, we revisit the narrow-line region size-luminosity relation. The area and radii of the [O III] emission-line regions are strongly correlated with the AGN luminosity inferred from the mid-infrared (15 $\mu$m rest-frame) with a power-law slope of $0.62^{+0.05}_{-0.06} \pm 0.10$ (statistical and systemic errors), consistent with previous spectroscopic findings. We discuss the implications for the physics of AGN emission-line region and future applications of this technique, which should be useful for current and next-generation imaging surveys to study AGN photoionization and feedback with large statistical samples.Comment: 20 pages, 13 figures, MNRAS submitte

Near-Infrared Spectroscopy of Carbon-Enhanced Metal-Poor Stars. I. A SOAR/OSIRIS Pilot Study

We report on an abundance analysis for a pilot study of seven Carbon-Enhanced Metal-Poor (CEMP) stars, based on medium-resolution optical and near-infrared spectroscopy. The optical spectra are used to estimate [Fe/H], [C/Fe], [N/Fe], and [Ba/Fe] for our program stars. The near-infrared spectra, obtained during a limited early science run with the new SOAR 4.1m telescope and the Ohio State Infrared Imager and Spectrograph (OSIRIS), are used to obtain estimates of [O/Fe] and 12C/13C. The chemical abundances of CEMP stars are of importance for understanding the origin of CNO in the early Galaxy, as well as for placing constraints on the operation of the astrophysical s-process in very low-metallicity Asymptotic Giant Branch (AGB) stars. This pilot study includes a few stars with previously measured [Fe/H], [C/Fe], [N/Fe],[O/Fe], 12C/13C, and [Ba/Fe], based on high-resolution optical spectra obtained with large-aperture telescopes. Our analysis demonstrates that we are able to achieve reasonably accurate determinations of these quantities for CEMP stars from moderate-resolution optical and near-infrared spectra. This opens the pathway for the study of significantly larger samples of CEMP stars in the near future. Furthermore, the ability to measure [Ba/Fe] for (at least the cooler) CEMP stars should enable one to separate stars that are likely to be associated with s-process enhancements (the CEMP-s stars) from those that do not exhibit neutron-capture enhancements (the CEMP-no stars).Comment: 27 pages, including 5 tables, 6 figures, accepted for publication in The Astronomical Journa

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials

BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and increased blood eosinophils. The aim was to establish whether subcutaneous reslizumab 110 mg can reduce exacerbation rates in these patients (study 1) or reduce maintenance oral corticosteroid dose in patients with corticosteroid-dependent asthma (study 2). METHODS: Both studies were randomised, double-blind, placebo-controlled, phase 3 studies. Entry criteria for study 1 were uncontrolled severe asthma, two or more asthma exacerbations in the previous year, a blood eosinophil count of 300 cells per μL or more (including no more than 30% patients with an eosinophil count <400 cells/μL), and at least a medium dose of inhaled corticosteroids with one or more additional asthma controllers. Patients in study 2 had severe asthma, a blood eosinophil count of 300 cells per μL or more, daily maintenance oral corticosteroid (prednisone 5-40 mg, or equivalent), and high-dose inhaled corticosteroids plus another controller. Patients were randomly assigned (1:1) to subcutaneous reslizumab (110 mg) or placebo once every 4 weeks for 52 weeks in study 1 and 24 weeks in study 2. Patients and investigators were masked to treatment assignment. Primary efficacy outcomes were frequency of exacerbations during 52 weeks in study 1 and categorised percentage reduction in daily oral corticosteroid dose from baseline to weeks 20-24 in study 2. Primary efficacy analyses were by intention to treat, and safety analyses included all patients who received at least one dose of study treatment. These studies are registered with ClinicalTrials.gov, NCT02452190 (study 1) and NCT02501629 (study 2). FINDINGS: Between Aug 12, 2015, and Jan 31, 2018, 468 patients in study 1 were randomly assigned to placebo (n=232) or subcutaneous reslizumab (n=236), and 177 in study 2 to placebo (n=89) or subcutaneous reslizumab (n=88). In study 1, we found no significant difference in the exacerbation rate between reslizumab and placebo in the intention-to-treat population (rate ratio 0·79, 95% CI 0·56-1·12; p=0·19). Subcutaneous reslizumab reduced exacerbation frequency compared with placebo in the subgroup of patients with blood eosinophil counts of 400 cells per μL or more (0·64, 95% CI 0·43-0·95). Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first exacerbation were observed for patients with higher trough serum reslizumab concentrations. In study 2, we found no difference between placebo and fixed-dose subcutaneous reslizumab in categorised percentage reduction in daily oral corticosteroid dose (odds ratio for a lower category of oral corticosteroid use in the reslizumab group vs the placebo group, 1·23, 95% CI 0·70-2·16; p=0·47). The frequency of adverse events and serious adverse events with reslizumab were similar to those with placebo in both studies. INTERPRETATION: Fixed-dose (110 mg) subcutaneous reslizumab was not effective in reducing exacerbation frequency in patients with uncontrolled asthma and increased blood eosinophils (≥300 cells/μL), or in reducing the daily maintenance oral corticosteroid dose in patients with oral corticosteroid-dependent severe eosinophilic asthma. Higher exposures than those observed with 110 mg subcutaneous reslizumab are required to achieve maximal efficacy. FUNDING: Teva Branded Pharmaceutical Products R&D

Automated Determination of [Fe/H] and [C/Fe] from Low-Resolution Spectroscopy

We develop an automated spectral synthesis technique for the estimation of metallicities ([Fe/H]) and carbon abundances ([C/Fe]) for metal-poor stars, including carbon-enhanced metal-poor stars, for which other methods may prove insufficient. This technique, autoMOOG, is designed to operate on relatively strong features visible in even low- to medium-resolution spectra, yielding results comparable to much more telescope-intensive high-resolution studies. We validate this method by comparison with 913 stars which have existing high-resolution and low- to medium-resolution to medium-resolution spectra, and that cover a wide range of stellar parameters. We find that at low metallicities ([Fe/H] < -2.0), we successfully recover both the metallicity and carbon abundance, where possible, with an accuracy of ~ 0.20 dex. At higher metallicities, due to issues of continuum placement in spectral normalization done prior to the running of autoMOOG, a general underestimate of the overall metallicity of a star is seen, although the carbon abundance is still successfully recovered. As a result, this method is only recommended for use on samples of stars of known sufficiently low metallicity. For these low-metallicity stars, however, autoMOOG performs much more consistently and quickly than similar, existing techniques, which should allow for analyses of large samples of metal-poor stars in the near future. Steps to improve and correct the continuum placement difficulties are being pursued.Comment: 8 pages, 7 figures; accepted for publication in A

Characterization of the KATRIN cryogenic pumping section

The KArlsruhe TRItium Neutrino (KATRIN) experiment aims to determine the effective anti-electron neutrino mass with a sensitivity of 0.2 eV/c$^2$ by using the kinematics of tritium $\beta$-decay. It is crucial to have a high signal rate which is achieved by a windowless gaseous tritium source producing 10$^{11}$ $\beta$-electrons per second. These are guided adiabatically to the spectrometer section where their energy is analyzed. In order to maintain a low background rate below 0.01 cps, one essential criteria is to permanently reduce the flow of neutral tritium molecules between the source and the spectrometer section by at least 14 orders of magnitude. A differential pumping section downstream from the source reduces the tritium flow by seven orders of magnitude, while at least another factor of 10$^7$ is achieved by the cryogenic pumping section where tritium molecules are adsorbed on an approximately 3 K cold argon frost layer. In this paper, the results of the cryogenic pumping section commissioning measurements using deuterium are discussed. The cryogenic pumping section surpasses the requirement for the flow reduction of 10$^7$ by more than one order of magnitude. These results verify the predictions of previously published simulations

Interactive effects between paylean™ (Ractopamine HCl) and dietary lysine on finishing pig growth performance, carcass characteristics and tissue accretion

A total of 432 pigs were used to evaluate the effects of Paylean and dietary lysine on finishing pig growth performance, carcass characteristics and tissue accretion. The 12 dietary treatments included Paylean (0, 4.5, and 9.0 g/ton) and 4 levels of lysine. For pigs fed no Paylean, lysine levels were 0.60, 0.80, 1.00, and 1.20%. For pigs fed 4.5 or 9.0 g/ton of Paylean, lysine levels were 0.80, 1.00, 1.20, and 1.40%. The results indicate that pigs fed Paylean need at least 1.0% dietary lysine to optimize growth, carcass parameters, and tissue accretion